Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208704 | 1.00 | HTR6 (0.50) | HTR6KHK | |
| SCHEMBL3629325 | 1.00 | HTR6 (0.50) | HTR6KHK | |
| SCHEMBL22527592 | 0.92 | HTR6 (0.53) | HTR6 | |
| SCHEMBL22527652 | 0.88 | HTR6 (0.57) | HTR6 | |
| SCHEMBL1159744 | 0.86 | HPGD (0.35) | HTR6 | |
| Hydrochloric Acid SCHEMBL5235947 | 0.84 | HPGD (0.38) | HTR6 | |
| SCHEMBL22527640 | 0.83 | HTR6 (0.56) | HTR6 | |
| SCHEMBL3720100 | 0.81 | HTR6 (0.37) | HTR6 | |
| Hydrochloric Acid SCHEMBL4255061 | 0.79 | HTR6 (0.35) | HTR6 | |
| Hydrochloric Acid SCHEMBL4263716 | 0.79 | HTR6 (0.35) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | Argonaut Therapeutics Limited (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | Argonaut Therapeutics Limited (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3010922-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| US-7547722-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2009-06-16 | — | — | US | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| EP-1543012-B1 | 6H-THIEN 2, 3-B]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-7268158-B2 | 6H-THIENO [2,3-b]pyrrole derivatives as antagonists of gonadotropin releasing hormone (GnRH) | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485731-B2 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | PRMT5, PRMT6, PRMT1 | HTR6 3159/4885KHK 4398/4885 |
| US-20080045517-A1 | 6H-THIENO[2,3-b]PYRROLE DERIVATIVES AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE (GNRH) | GNRHR, PRLHR, GHRHR | HTR6 324/4885KHK 3540/4885 |
| US-20200325128-A1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | PRMT5, PRMT6, PRMT1 | HTR6 3600/4885KHK 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.